AR119334A1 - Inhibidores de la traducción y sus usos - Google Patents

Inhibidores de la traducción y sus usos

Info

Publication number
AR119334A1
AR119334A1 ARP200101871A ARP200101871A AR119334A1 AR 119334 A1 AR119334 A1 AR 119334A1 AR P200101871 A ARP200101871 A AR P200101871A AR P200101871 A ARP200101871 A AR P200101871A AR 119334 A1 AR119334 A1 AR 119334A1
Authority
AR
Argentina
Prior art keywords
inhibitors
translation
translation inhibitors
eif4a
mnk
Prior art date
Application number
ARP200101871A
Other languages
English (en)
Inventor
Kevin R Webster
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of AR119334A1 publication Critical patent/AR119334A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composiciones que comprenden una pluralidad de inhibidores que actúan sobre factores de la traducción implicados en la iniciación de la traducción de mARN dependiente de cap, que incluyen inhibidores contra eIF4A, eIF4E, MNK, o cualquier combinación de estos. También métodos para el tratamiento de trastornos hiperproliferativos, tales como cáncer, con tratamientos conjuntos de inhibidores de la traducción.
ARP200101871A 2019-07-02 2020-07-01 Inhibidores de la traducción y sus usos AR119334A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962869897P 2019-07-02 2019-07-02

Publications (1)

Publication Number Publication Date
AR119334A1 true AR119334A1 (es) 2021-12-09

Family

ID=71452520

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101871A AR119334A1 (es) 2019-07-02 2020-07-01 Inhibidores de la traducción y sus usos

Country Status (4)

Country Link
JP (1) JP2021008453A (es)
AR (1) AR119334A1 (es)
TW (1) TW202114681A (es)
WO (1) WO2021001743A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114404400A (zh) * 2022-01-24 2022-04-29 深圳承启生物科技有限公司 不占用核糖体资源的翻译抑制剂作为抗肿瘤药物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
NZ277498A (en) 1993-12-17 1998-03-25 Novartis Ag Rapamycin derivatives
PT833828E (pt) 1995-06-09 2003-02-28 Novartis Ag Derivados de rapamicina
GB9914480D0 (en) 1999-06-21 1999-08-18 Univ Dundee Use of peptides
US7737134B2 (en) 2002-03-13 2010-06-15 The Texas A & M University System Anticancer agents and use
WO2003077862A2 (en) 2002-03-13 2003-09-25 The Texas A & M University System Potent, simplified derivatives of immunosuppressive agents
US7425544B2 (en) 2003-09-18 2008-09-16 Eli Lilly And Company Modulation of eIF4E expression
JP5225691B2 (ja) 2005-01-21 2013-07-03 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ タンパク質合成の調節
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP5677425B2 (ja) 2009-06-29 2015-02-25 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのピリミジノン
US8680108B2 (en) 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US9018348B2 (en) 2010-04-27 2015-04-28 Agency For Science, Technology And Research eIF4E binding peptides
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2013016658A1 (en) 2011-07-27 2013-01-31 The Ohio State University Research Foundation Silvestrol, silvestrol analogs and uses thereof
KR102507287B1 (ko) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
JP6313779B2 (ja) * 2012-11-30 2018-04-18 ノボメディックス, エルエルシーNovomedix, Llc 置換ビアリールスルホンアミドおよびその利用
CN105263950A (zh) 2013-03-21 2016-01-20 新加坡科技研究局 钉合eIF4E相互作用肽
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
US10407444B2 (en) 2015-03-31 2019-09-10 The Texas A&M University System Alpha-amino pateamine A derivatives and methods for treating chronic lymphocytic leukemia
WO2016172010A1 (en) 2015-04-20 2016-10-27 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
EP3397774A1 (en) * 2015-12-31 2018-11-07 Effector Therapeutics Inc. Mnk biomarkers and uses thereof
KR102641269B1 (ko) * 2017-05-24 2024-02-26 이펙터 테라퓨틱스, 인크. 개선된 항종양 면역 반응을 위한 조성물 및 방법

Also Published As

Publication number Publication date
TW202114681A (zh) 2021-04-16
JP2021008453A (ja) 2021-01-28
WO2021001743A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
CL2019000820A1 (es) Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2020000299A1 (es) Compuestos, composiciones y métodos.
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
CL2017001956A1 (es) Oligomeros antisentido de tau y uso de los mismos
CL2018001404A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
BR112018073328A2 (pt) combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
CL2017001046A1 (es) Inhibidoes del bromodominio
MX2021014815A (es) Metodos para el tratamiento de la inflamacion o el dolor neuropatico.
CO2018000224A2 (es) Compuestos inhibidores de la señalización de la vía de notch
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
BR112018009311A2 (pt) ?método para tratar um sujeito humano sofrendo de tma persistente associada com transplante de célula tronco hematopoiética?
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
ECSP19084085A (es) Inhibidores pirazólicos de magl
CO2016000671A1 (es) Construcciones de variantes de sirp-alfa y sus usos
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
BR112021017774A2 (pt) Dose baixa de citocina coadministrada com irgd para tratar câncer
AR119334A1 (es) Inhibidores de la traducción y sus usos
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
NI201900128A (es) Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico, usos y composiciones farmacéuticas de esta
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.